(Q83093506)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596125%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596125%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

Jonathan E Dowell

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596125%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

John D Minna

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596125%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 April 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596125%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Oncology

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596125%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596125%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596125%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

170-171

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596125%20AND%20SRC:MED&resulttype=core&format=json

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0476

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0476

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0476

7 January 2021

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0476

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0476

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0476

7 January 2021

The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0476

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0476

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0476

7 January 2021

Identifiers

DOI

10.1038/NCPONC0476

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596125%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference